Biolase Stock Book Value Per Share
| BIOLDelisted Stock | USD 0.05 0.02 27.46% |
BIOLASE fundamentals help investors to digest information that contributes to BIOLASE's financial success or failures. It also enables traders to predict the movement of BIOLASE Stock. The fundamental analysis module provides a way to measure BIOLASE's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BIOLASE stock.
BIOLASE |
BIOLASE Company Book Value Per Share Analysis
BIOLASE's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current BIOLASE Book Value Per Share | (0.06) X |
Most of BIOLASE's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BIOLASE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of BIOLASE is about -0.058 times. This is 96.59% lower than that of the Health Care Equipment & Supplies sector and 104.17% lower than that of the Health Care industry. The book value per share for all United States stocks is 100.0% higher than that of the company.
BIOLASE Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BIOLASE's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BIOLASE could also be used in its relative valuation, which is a method of valuing BIOLASE by comparing valuation metrics of similar companies.BIOLASE is currently under evaluation in book value per share category among its peers.
BIOLASE Fundamentals
| Return On Equity | -5.05 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (0.44) % | |||
| Operating Margin | (0.45) % | |||
| Current Valuation | 13.65 M | |||
| Shares Outstanding | 33.4 M | |||
| Shares Owned By Insiders | 0.32 % | |||
| Shares Owned By Institutions | 8.97 % | |||
| Number Of Shares Shorted | 2.1 M | |||
| Price To Earning | (7.23) X | |||
| Price To Book | 0.77 X | |||
| Price To Sales | 0.1 X | |||
| Revenue | 49.16 M | |||
| Gross Profit | 16.53 M | |||
| EBITDA | (15.14 M) | |||
| Net Income | (20.63 M) | |||
| Cash And Equivalents | 9.96 M | |||
| Cash Per Share | 1.39 X | |||
| Total Debt | 17.91 M | |||
| Debt To Equity | 1.07 % | |||
| Current Ratio | 2.46 X | |||
| Book Value Per Share | (0.06) X | |||
| Cash Flow From Operations | (14.09 M) | |||
| Short Ratio | 1.09 X | |||
| Earnings Per Share | (11.97) X | |||
| Price To Earnings To Growth | (0.22) X | |||
| Target Price | 1.95 | |||
| Number Of Employees | 157 | |||
| Beta | 0.75 | |||
| Market Capitalization | 4.31 M | |||
| Total Asset | 35.1 M | |||
| Retained Earnings | (316.8 M) | |||
| Working Capital | 5.2 M | |||
| Current Asset | 34.8 M | |||
| Current Liabilities | 15.11 M | |||
| Net Asset | 35.1 M |
About BIOLASE Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BIOLASE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BIOLASE using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BIOLASE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in BIOLASE Stock
If you are still planning to invest in BIOLASE check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BIOLASE's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |